Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $8000.0.

  • Seres Therapeutics' Capital Expenditures fell 9379.84% to $8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $313000.0, marking a year-over-year decrease of 7317.91%. This contributed to the annual value of $380000.0 for FY2024, which is 9523.51% down from last year.
  • Seres Therapeutics' Capital Expenditures amounted to $8000.0 in Q3 2025, which was down 9379.84% from $160000.0 recorded in Q2 2025.
  • Seres Therapeutics' 5-year Capital Expenditures high stood at $4.1 million for Q3 2021, and its period low was $8000.0 during Q3 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $1.2 million (2022), whereas its average is $1.5 million.
  • In the last 5 years, Seres Therapeutics' Capital Expenditures skyrocketed by 610000.0% in 2021 and then crashed by 9847.59% in 2024.
  • Over the past 5 years, Seres Therapeutics' Capital Expenditures (Quarter) stood at $1.6 million in 2021, then soared by 119.33% to $3.5 million in 2022, then tumbled by 74.66% to $877000.0 in 2023, then crashed by 89.74% to $90000.0 in 2024, then crashed by 91.11% to $8000.0 in 2025.
  • Its last three reported values are $8000.0 in Q3 2025, $160000.0 for Q2 2025, and $55000.0 during Q1 2025.